Page 101 - Read Online

Page 8 of 10 Berghen et al. J Cancer Metastasis Treat 2021;7:58 https://dx.doi.org/10.20517/2394-4722.2021.123

Critical review of the manuscript, advice on medical oncology: Beuselinck B
Critical review of the manuscript, advice on surgical items: Decaestecker K
Creation figure 1, critical review of the manuscript, advice on technical parts of radiation therapy: Poels K
Critical review of the manuscript: Otte F
Critical review of the manuscript, advice on surgical items: Joniau S
Critical review of the manuscript, advice on proton beam therapy: Haustermans K
Content of the manuscript, data interpretation, writing of the manuscript: De Meerleer G

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol 2019;75:74-84. DOI PubMed PMC
2. Ljungberg B, Albiges L, Bedke J. EAU guidelines on renal cell carcinoma. Available from: https://uroweb.org/guideline/renal-cell-
carcinoma/ [Last accessed on 14 Sep 2021].
3. Rühle A, Andratschke N, Siva S, Guckenberger M. Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?
Clin Transl Radiat Oncol 2019;18:104-12. DOI PubMed PMC
4. Frick MA, Chhabra AM, Lin L, Simone CB 2nd. First ever use of proton stereotactic body radiation therapy delivered with curative
intent to bilateral synchronous primary renal cell carcinomas. Cureus 2017;9:e1799. DOI PubMed PMC
5. Correa RJ, Louie AV, Zaorsky NG, et al. The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a
systematic review and meta-analysis. Eur Urol Focus 2019;5:958-69. DOI PubMed
6. De Meerleer G, Khoo V, Escudier B, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol 2014;15:e170-7. DOI PubMed
7. Sathishkumar S, Boyanovsky B, Karakashian AA, et al. Elevated sphingomyelinase activity and ceramide concentration in serum of
patients undergoing high dose spatially fractionated radiation treatment: implications for endothelial apoptosis. Cancer Biol Ther
2005;4:979-86. DOI PubMed
8. Siva S, Kothari G, Muacevic A, et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol
2017;14:549-63. DOI PubMed
9. Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a
rare event clinically relevant. Cancer Treat Rev 2015;41:503-10. DOI PubMed PMC
10. Tselis N, Chatzikonstantinou G. Treating the Chameleon: radiotherapy in the management of Renal Cell Cancer. Clin Transl Radiat
Oncol 2019;16:7-14. DOI PubMed PMC
11. Ingrosso G, Becherini C, Francolini G, et al. Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney
cancer: A systematic review. Crit Rev Oncol Hematol 2021;159:103242. DOI PubMed
12. Siva S, Correa RJM, Warner A, et al. Stereotactic ablative radiotherapy for ≥T1b primary renal cell carcinoma: a report from the
international radiosurgery oncology consortium for kidney (IROCK). Int J Radiat Oncol Biol Phys 2020;108:941-9. DOI PubMed
13. Correa RJM, Ahmad B, Warner A, et al. A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an
alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma. Radiat Oncol 2018;13:47. DOI
PubMed PMC
14. Simmons MN, Weight CJ, Gill IS. Laparoscopic radical versus partial nephrectomy for tumors >4 cm: intermediate-term oncologic
and functional outcomes. Urology 2009;73:1077-82. DOI PubMed